85 related articles for article (PubMed ID: 25804226)
1. Metabolic changes during development of Walker-256 carcinosarcoma resistance to doxorubicin.
Todor IN; Lukyanova NY; Shvets YV; Lozovska YV; Chekhun VF
Exp Oncol; 2015 Mar; 37(1):19-22. PubMed ID: 25804226
[TBL] [Abstract][Full Text] [Related]
2. Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells.
Miccadei S; Fanciulli M; Bruno T; Paggi MG; Floridi A
Oncol Res; 1996; 8(1):27-35. PubMed ID: 8704284
[TBL] [Abstract][Full Text] [Related]
3. Structural changes of serum albumin in response to oxidative stress caused by Walker-256 carcinosarcoma growth.
Sarnatskaya VV; Yushko LA; Prokopenko IV; Hudenko NV; Maslenny VN; Paziuk LM; Bubnovskaya LN; Nikolaev VG
Exp Oncol; 2020 Mar; 42(1):40-45. PubMed ID: 32231185
[TBL] [Abstract][Full Text] [Related]
4. METALLOPROTEINS DURING DEVELOPMENT OF WALKER-256 CARCINOSARCOMA RESISTANT PHENOTYPE.
Chekhun VF; Lozovska YV; Burlaka AP; Ganusevich II; Shvets YV; Lukianova NY; Todor IM; Demash DV; Pavlova AA; Naleskina LA
Ukr Biochem J; 2015; 87(2):103-12. PubMed ID: 26255344
[TBL] [Abstract][Full Text] [Related]
5. Remodulating effect of doxorubicin on the state of iron-containing proteins, and redox characteristics of tumor with allowance for its sensitivity to cytostatic agents.
Chekhun VF; Lozovska YV; Burlaka AP; Ganusevich LI; Shvets YV; Lukyanova NY; Todor IM; Tregubova NA; Naleskina LA
Ukr Biochem J; 2016; 88(1):99-108. PubMed ID: 29227592
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C metabolic flux analysis.
Strigun A; Wahrheit J; Niklas J; Heinzle E; Noor F
Toxicol Sci; 2012 Feb; 125(2):595-606. PubMed ID: 22048646
[TBL] [Abstract][Full Text] [Related]
7. Oxidative phosphorylation activation is an important characteristic of DOX resistance in hepatocellular carcinoma cells.
Wu L; Zhao J; Cao K; Liu X; Cai H; Wang J; Li W; Chen Z
Cell Commun Signal; 2018 Feb; 16(1):6. PubMed ID: 29402287
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis repressor with caspase recruitment domain contributes to chemotherapy resistance by abolishing mitochondrial fission mediated by dynamin-related protein-1.
Wang JX; Li Q; Li PF
Cancer Res; 2009 Jan; 69(2):492-500. PubMed ID: 19147562
[TBL] [Abstract][Full Text] [Related]
9. Morphological features of doxorubicin-resistant Walker 256 carcinosarcoma and response of mast cells.
Boroday NV; Chekhun VF
Exp Oncol; 2018 Mar; 40(1):42-47. PubMed ID: 29600974
[TBL] [Abstract][Full Text] [Related]
10. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity.
Polimeni M; Voena C; Kopecka J; Riganti C; Pescarmona G; Bosia A; Ghigo D
Biochem J; 2011 Oct; 439(1):141-9. PubMed ID: 21679161
[TBL] [Abstract][Full Text] [Related]
11. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.
Carvalho RA; Sousa RP; Cadete VJ; Lopaschuk GD; Palmeira CM; Bjork JA; Wallace KB
Toxicology; 2010 Apr; 270(2-3):92-8. PubMed ID: 20132857
[TBL] [Abstract][Full Text] [Related]
12. Investigation of Mitochondrial Metabolic Response to Doxorubicin in Prostate Cancer Cells: An NADH, FAD and Tryptophan FLIM Assay.
Alam SR; Wallrabe H; Svindrych Z; Chaudhary AK; Christopher KG; Chandra D; Periasamy A
Sci Rep; 2017 Sep; 7(1):10451. PubMed ID: 28874842
[TBL] [Abstract][Full Text] [Related]
13. Reduction of the growth rate of the Walker 256 tumor in rats by rhodamine 6G together with hypoglycemia.
Fearon KC; Plumb JA; Burns HJ; Calman KC
Cancer Res; 1987 Jul; 47(14):3684-7. PubMed ID: 3594433
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
[TBL] [Abstract][Full Text] [Related]
15. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine.
Fanciulli M; Bruno T; Giovannelli A; Gentile FP; Di Padova M; Rubiu O; Floridi A
Clin Cancer Res; 2000 Apr; 6(4):1590-7. PubMed ID: 10778993
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of biochemical and morphological parameters in rats with Walker 256 and Walker 256/DOX carcinosarcoma.
Yushko LA; Sarnatskaya VV; Sakhno LA; Hudenko NV; Paziuk LM; Maslenny VN; Melnyk VO; Nikolaev VG
Exp Oncol; 2021 Mar; 43(1):21-25. PubMed ID: 33785723
[TBL] [Abstract][Full Text] [Related]
17. Effect of a subcutaneously growing Walker 256 carcinosarcoma on host tissue mitochondrial function and magnesium content.
Cummings J; Willmott N; Calman KC
Cancer Res; 1984 Apr; 44(4):1333-6. PubMed ID: 6704952
[TBL] [Abstract][Full Text] [Related]
18. Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma.
Bean JF; Qiu YY; Yu S; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2014 Jun; 49(6):981-4; discussion 984. PubMed ID: 24888847
[TBL] [Abstract][Full Text] [Related]
19. [Effect of doxorubicin on oxidative phosphorylation in the brain mitochondria].
Khazanov VA; Borodina SA; Smirnova NB
Biull Eksp Biol Med; 1999 Oct; 128(10):445-7. PubMed ID: 10599507
[No Abstract] [Full Text] [Related]
20. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
